13 results about "P2X3 Receptor" patented technology

The invention discloses imidazopyridine derivatives and application thereof, a pharmaceutical composition and a pharmaceutical preparation, and belongs to the technical field of medical chemistry. The technical problems to be solved are that the existing P2X3 receptor inhibitor is poor in safety, low in P2X3 or P2X2 / 3 selectivity, poor in metabolic stability and the like. According to the key points of the technical scheme, the imidazopyridine derivative is selected from a compound as shown in a formula I or a racemate, a stereoisomer, a geometric isomer, a tautomer, a nitrogen oxide, a hydrate, an isotope label, a solvate, a polymorphic substance, a metabolite, an ester, a pharmaceutically acceptable salt or a prodrug thereof.

The application discloses an imidazopyridine derivative and application, a pharmaceutical composition and a pharmaceutical preparation, and belongs to the technical field of medicinal chemistry. The technical problems to be solved are that existing P2X3 receptor inhibitors have poor safety, low selectivity for P2X3 or P2X2 / 3 and poor metabolic stability. The technical solution is that an imidazopyridine derivative is selected from the compounds shown in the formula I or racemates, stereoisomers, geometric isomers, tautomers, nitroxides, hydrates, isotopically labeled compounds, solvates, polymorphs, metabolites, esters, pharmaceutically acceptable salts or prodrugs.

The application provides a preparation method of an imidazopyridine compound shown as formula IV and intermediates thereof shown as formula I or formula II. The imidazopyridine compound shown as formula IV can antagonize P2X3 receptors and has the effects of inhibiting cough and analgesia.

Pharmaceutical compositions comprising (i) a P2X3 receptor antagonist and (ii) a carbonic anhydrase inhibitor (CAI), and methods of treating sleep apnea and conditions associated with pharyngeal airway collapse are described herein.

The present invention relates to compounds of Formula I (hereinafter referred to as P2X3 inhibitors) that inhibit P2X purinergic receptor 3; in particular, the present invention relates to compounds that are pyridopyrimidine derivatives, methods of making such compounds, pharmaceutical compositions containing them and therapeutic uses thereof. The compounds of the present invention are useful in the treatment of a number of disorders associated with P2X3 receptor mechanisms, such as respiratory diseases, including cough, asthma, idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD).

An N-formamidopyrazoline derivative is a compound having General Formula (I) or an enantiomer, a diastereomer, an epimer and a racemate thereof, or a pharmaceutically acceptable salt thereof. The compound is an antagonist of a ligand-gated non-selective cation channel receptor subtype P2X3, and can be used for treating or preventing various diseases mediated by the receptor P2X3.

The invention provides a heterocyclic compound as a P2X3 receptor inhibitor. The heterocyclic compound is a compound as shown in a formula (I), an isotope variant, a tautomer or a stereoisomer. The invention also provides a pharmaceutical composition containing the compound, and application of the pharmaceutical composition in treatment of diseases related to P2X3.

The application belongs to the technical field of short peptide medicine, and specifically discloses a Maged1 competitive short peptide and application thereof.The Maged1 competitive short peptide is short peptide MP1 or short peptide MP2, and the amino acid sequence is shown as SEQ ID No.1 or SEQ ID No.2.Experiments prove that the Maged1 competitive short peptide can compete with Maged1 to combine with P2X3 receptors, thereby inhibiting the activation of Maged1 on P2X3 receptors, and has a good clinical application prospect in the treatment of chronic pain.

The present application provides a new compound which effectively antagonizes P2X3 receptor, which is a compound shown in formula I, a tautomer, a stereoisomer, a hydrate, a solvate, a pharmaceutically acceptable salt or a prodrug thereof, a preparation method thereof, and a use thereof in the preparation of a medicine

The present application provides a new compound which effectively antagonizes P2X3 receptor, which is a compound shown in formula I, a tautomer, a stereoisomer, a pharmaceutically acceptable salt thereof, a preparation method thereof, and a use thereof in the preparation of a medicine.

The invention discloses imidazopyridine derivatives as well as a preparation method, a pharmaceutical composition and application thereof, and belongs to the technical field of pharmaceutical synthesis. The technical problem to be solved is to provide a P2X3 receptor antagonist of an imidazopyridine derivative with a new structure, and the compound has good P2X3 selectivity, low toxicity, good metabolic stability and small taste influence, and has good prospects in treatment of P2X3 receptor dysfunction diseases, especially in treatment of neurogenic diseases. According to the key point of the technical scheme, the imidazopyridine derivative is selected from a compound as shown in a formula I or a racemate, a stereoisomer, a geometric isomer, a tautomer, nitrogen oxide, hydrate, an isotope label, a solvate, a polymorphic substance, a metabolite, ester, pharmaceutically acceptable salt or prodrug of the compound, wherein the formula I is shown in the specification.

The invention provides a heterocyclic compound as a P2X3 receptor inhibitor. The heterocyclic compound is a compound as shown in a formula (I), an isotope variant, a tautomer or a stereoisomer. The invention also provides a pharmaceutical composition containing the compound, and application of the pharmaceutical composition in treatment of diseases related to P2X3.

This invention, entitled "Imidazolopyridine Derivatives, Preparation Methods, Pharmaceutical Compositions, and Applications thereof," belongs to the field of pharmaceutical synthesis technology. The technical problem to be solved is to provide a novel imidazopyridine derivative P2X3 receptor antagonist. These compounds exhibit good P2X3 selectivity, low toxicity, good metabolic stability, and minimal impact on taste, showing great promise in treating P2X3 receptor dysfunction diseases, particularly neurogenic diseases. The key technical solution is an imidazopyridine derivative selected from compounds represented by Formula I or their racemic, stereoisomer, geometric isomer, tautomer, nitride, hydrate, isotope-labeled, solvate, polymorph, metabolite, ester, pharmaceutically acceptable salt, or prodrug: Formula I.